Yelin Lapidot Holdings Management Ltd. Sells 2,630 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Yelin Lapidot Holdings Management Ltd. decreased its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,873 shares of the company’s stock after selling 2,630 shares during the period. Yelin Lapidot Holdings Management Ltd. owned about 0.07% of Arvinas worth $899,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after buying an additional 440 shares in the last quarter. Rhumbline Advisers increased its position in shares of Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after acquiring an additional 754 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares during the period. KBC Group NV raised its stake in shares of Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arvinas by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after purchasing an additional 1,367 shares during the period. 95.19% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares in the company, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is currently owned by insiders.

Arvinas Stock Up 0.7 %

ARVN stock opened at $17.26 on Friday. The stock has a market capitalization of $1.19 billion, a PE ratio of -6.23 and a beta of 1.88. Arvinas, Inc. has a 52 week low of $16.07 and a 52 week high of $51.51. The firm has a 50 day moving average of $18.37 and a 200 day moving average of $22.72.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the prior year, the company earned ($2.53) earnings per share. On average, equities research analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Analysts Set New Price Targets

ARVN has been the subject of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $57.00 target price on shares of Arvinas in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. BTIG Research started coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price objective (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Arvinas currently has a consensus rating of “Buy” and an average target price of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.